BROOMFIELD, CO–(Marketwired – March 24, 2016) – ViroCyt®, the leader in rapid virus quantification, announced today that it has developed and launched an antibody-based detection system for influenza capable of determining virus titer for both flu A and flu B during a one minute analysis.
Every year, the flu virus causes millions of cases of illness and hundreds of thousands of deaths. The emergence of potentially pandemic strains in previous years has highlighted the need for faster methods of creating life-saving vaccines. To this end, significant investments have been made in new technologies. A primary bottleneck, however, has historically been a lack of rapid analytical systems capable of allowing in-process monitoring during the manufacturing process.
“We see the ability to provide real-time tracking of virus growth and purification as a significant step towards delivering effective vaccines to the global healthcare system faster and at lower cost,” stated Robert Kline, President and Chief Executive Officer of ViroCyt. “ViroTag® INVX and the Virus Counter® 3100 provide a potent combination that will transform how current and future flu vaccines are created.”
In extensive studies, ViroTag INVX has demonstrated the ability to recognize all influenza A and B strains examined, as well as Virus-Like Particles—also called VLPs—that are created using influenza proteins. This versatility is critically important since both are used to create vaccines against the flu.
“An indication of the potential impact of this technology is the participation of the world’s largest flu vaccine manufacturer, Sanofi Pasteur, in the beta testing of ViroTag INVX,” said Dr. Michael Olszowy, ViroCyt’s Chief Technology Officer. “I am delighted to share that Dr. Daniel Vellom, Senior Director of Global Technology Innovation at Sanofi Pasteur, will be presenting these results during his talk ‘Improving the pace and efficiency of viral vaccine development’ at 12:10pm on Wednesday, March 30 at the World Vaccine Congress taking place in Washington, DC.”
ViroCyt has developed a novel approach enabling direct, biologically-specific quantification of viruses in minutes rather than the days or weeks required by more traditional methods. Marketed under the tradename ViroTag®, this new product category utilizes a fluorescently-labeled, high-affinity antibody targeted to the virus of interest. During a 1-minute sample analysis, the preparation is evaluated with the Virus Counter® 3100, an instrument developed expressly for the purpose of real-time virus quantification.
About ViroCyt, Inc.
ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.
Michael Artinger Vice President, Marketing & Strategic Partnering
ViroCyt, Incorporated +1-720-599-3700 email@example.com